Cargando…
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
Although Bacillus Calmette-Guérin (BCG) is the most successful immunotherapy for high-risk non-muscle-invasive bladder cancer, approximately 30% of patients are unresponsive to treatment. New biomarkers are important to identify patients who will benefit most from BCG during a worldwide BCG shortage...
Autores principales: | Pichler, Renate, Fritz, Josef, Zavadil, Claudia, Schäfer, Georg, Culig, Zoran, Brunner, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129981/ https://www.ncbi.nlm.nih.gov/pubmed/27221038 http://dx.doi.org/10.18632/oncotarget.9537 |
Ejemplares similares
-
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007) -
Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019) -
Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016) -
Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
por: Madbouly, Khaled
Publicado: (2013) -
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)